Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.46 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL309818 | 0.93 | IDH1 (0.41) | EPHX2TRPV4OPRK1GAAMEN1 | |
| SCHEMBL2832484 | 0.85 | EPHX2 (0.48) | EPHX2TRPV4GAAMEN1KMT2A | |
| SCHEMBL2831496 | 0.78 | IDH1 (0.44) | EPHX2GAAMEN1KMT2AGBA1 | |
| SCHEMBL308313 | 0.75 | EPHX2 (0.48) | EPHX2TRPV4GAATSHR | |
| SCHEMBL2835422 | 0.74 | EPHX2 (0.51) | EPHX2TRPV4MEN1KMT2AMAPT | |
| SCHEMBL2833230 | 0.72 | EPHX2 (0.51) | EPHX2OPRK1MEN1KMT2AMAPT | |
| SCHEMBL308532 | 0.71 | EPHX2 (0.47) | EPHX2TRPV4GAAMEN1KMT2A | |
| SCHEMBL14132639 | 0.71 | EPHX2 (0.47) | EPHX2TRPV4GAAMEN1KMT2A | |
| SCHEMBL13373239 | 0.71 | EPHX2 (0.44) | EPHX2TRPV4GAAMEN1KMT2A | |
| SCHEMBL12965392 | 0.71 | GAA (0.42) | EPHX2TRPV4GAAHCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093249-B2 | Pyrazolo[1,5-A]pyrimidine-carbonyl-piperazine derivatives | Convergence Pharmaceuticals Limited (GB) | 2012-01-10 | — | — | US | disclosed |
| US-20100016330-A1 | Novel Derivatives | Convergence Pharmaceuticals Limited (GB) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016330-A1 | Novel Derivatives | CACNB2, CACNA1B, CACNA1D | EPHX2 3915/4885TRPV4 44/4885OPRK1 1030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.